ON-EPIC Oral nitrate supplementation to enhance pulmonary rehabilitation in chronic obstructive pulmonary disease

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory Chronic obstructive pulmonary disease (COPD)

Matthew Pavitt, Rebecca Tanner, Adam Lewis, Sara Buttery, Bhavin Mehta et al. (14 authors)

Thorax2020-05-0646 citations

10.1136/thoraxjnl-2019-214278

T5 Oral dietary nitrate supplementation to enhance pulmonary rehabilitation in chronic obstructive pulmonary disease: a multi-centre, double blind, placebo-controlled, parallel group study

MJ Pavitt, RJ Tanner, AP Lewis, SC Buttery, Bhavin Mehta et al. (14 authors)

2018-11-161 citations

10.1136/thorax-2018-212555.5

Acute Dietary Nitrate Supplementation and Exercise Performance in COPD: A Double-Blind, Placebo-Controlled, Randomised Controlled Pilot Study

Katrina Curtis, Katie A. O’Brien, Rebecca Tanner, Juliet I. Polkey, Magdalena Minnion et al. (9 authors)

PLoS ONE2015-12-2354 citations

10.1371/journal.pone.0144504

Interventions

Beetroot juice drink or matched nitrate-depleted placebo.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients will need to have a clinical and spirometric diagnosis of COPD, GOLD stage II-IV and with an MRC score of 3-5 or to be functionally limited

Exclusion criteria

Exclusion criteria: 1. Clinically unstable patients (within one month of exacerbation) 2. Within one month of completing pulmonary rehabilitation 3. Significant comorbidity limiting exercise tolerance 4. Significant renal impairment (estimated glomerular filtration rate (eGFR) <50 ml.min-1) 5. Hypotension (systolic blood pressure <100 mmHg) 6. Pregnancy 7. Use of nitrate based medication 8. Other reason for benefit from nitrate supplementation (ischaemic heart disease, peripheral arterial disease) 9. Use of long-term oxygen therapy

Design outcomes

Primary

Measure	Time frame
Incremental shuttle walking test (ISWT) distance	—

Secondary

Measure	Time frame
All outcomes measured at 8 weeks: 1. Health status measured by the COPD assessment test score (CAT) and the Hospital Anxiety and Depression scale (HADs) 2. Fat free mass determined by bioelectrical impedance analysis 3. Flow mediated dilatation (FMD) Removed 16/04/2018: 4. Blood plasma NO2 levels (a marker of NO production and availability) as an exploratory variable	—

Countries

United Kingdom

Outcome results

None listed